What is the role of selpercatinib (Retevmo) in the treatment of non-small cell lung cancer (NSCLC)?

Updated: Jun 05, 2020
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

Selpercatinib is the first targeted therapy to be approved by the FDA for tumors that have rearranged during transfection (RET) mutations. It is indicated for metastatic RET-fusion–positive NSCLC. 

Accelerated approval in May 2020 for NSCLC was based on the open-label LIBRETTO-001 phase I/II clinical trial (n = 144). ORR was 64% in treatment experienced patients (n = 105) and 85% in treatment naïve patients (n = 39). The phase III confirmatory trial (LIBRETTO-431) is under way. [202]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!